What AMH Predicts About IVF and What It Leaves Out

Does AMH Predict IVF Success?

Not reliably, and not on its own. AMH (anti-Müllerian hormone) is a blood test that estimates how many eggs remain in reserve, and clinics use it to help plan stimulation medication. But the outcome data that actually tracks IVF success is organized around age, diagnosis, and cycle number — the national SART registry reports live-birth rates broken out by age band, not by AMH level 1Ref 1Society for Assisted Reproductive Technology (SART) (2024).National Summary Report (SART CORS Online).Supports that US national IVF/ART outcomes are reported by patient age band and by cycle, not by AMH level, and grounds how SART defines primary/cumulative/per-patient success groupings..

The CDC's own personalized success estimator works the same way: it calculates an individual's chance of a live birth using age, height and weight, and diagnosis — not an AMH value 2Ref 2Centers for Disease Control and Prevention (2024).IVF Success Estimator.Supports that the CDC's own individualized IVF success estimator calculates a live-birth chance from age, height/weight, and diagnosis — not from an AMH value.. That absence is worth sitting with. If AMH reliably forecast whether a cycle would end in a baby, the tools built specifically to forecast that outcome would ask for it.

What AMH Actually Measures

AMH is produced by small follicles in the ovaries, and clinics use it to estimate how many eggs are likely available before planning a stimulation protocol. Where a specific result falls on an AMH percentile by age chart can shift a medication plan or move up a conversation about egg freezing age math, but a lab report number is not the same thing as a verdict on whether a woman can conceive.

AMH (anti-Müllerian hormone) does not predict monthly fertility the way an ovulation test does — it speaks to egg quantity on a given day, not to the odds of a given month, or a given IVF cycle, ending in a birth.

A result is usually read alongside other pieces of the picture — age most of all, but also antral follicle count and a history of how prior cycles have gone — rather than in isolation. Two women with an identical AMH number can walk into very different conversations depending on what else is true about them, which is part of why a bare number quoted out of context, on a forum or from a mail-in kit, tends to cause more anxiety than clarity.

What the National Outcome Data Actually Tracks

National ART statistics are built for exactly this kind of question, and they are worth reading directly rather than through a clinic's marketing page. The CDC's National ART Surveillance System defines how a cycle, a pregnancy, and a live birth are counted, and it is explicit that national figures are noncumulative snapshots of a single reporting year rather than a per-patient prediction 3Ref 3Centers for Disease Control and Prevention (2024).NASS Technical Notes.Supports how the CDC's National ART Surveillance System defines and counts cycles, pregnancies, and live births, and that national success figures are noncumulative single-year snapshots rather than individual predictions..

That distinction matters for reading any success-rate table honestly: a clinic's live-birth rate per cycle answers a different question than what the odds look like across three attempts, and neither one is calculated from an AMH value in the first place. SART's own reporting groups outcomes by age band precisely because age, not a single hormone reading, is the variable that reliably separates one outcome distribution from another across hundreds of thousands of cycles 1Ref 1Society for Assisted Reproductive Technology (SART) (2024).National Summary Report (SART CORS Online).Supports that US national IVF/ART outcomes are reported by patient age band and by cycle, not by AMH level, and grounds how SART defines primary/cumulative/per-patient success groupings..

Why Age and Cycle Number Carry the Predictive Weight

Large cohort data make the case plainly. In one study of more than 156,000 women, the live-birth rate on a first IVF cycle was about 29.5%, and the cumulative, prognosis-adjusted rate rose to roughly 65% by the sixth cycle for the group overall — but for women aged 40 to 42, those figures were far lower, about 12% on the first cycle and 31.5% by the sixth 4Ref 4Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.Supports the specific first-cycle and cumulative live-birth rates by age (approximately 29.5% first-cycle and 65% cumulative by cycle six overall, versus about 12% and 31.5% for ages 40-42), showing age and cycle number driving IVF outcomes..

A first-cycle live-birth rate of ~29.5% became ~65% cumulative by cycle six for the full cohort, but only ~31.5% by cycle six for women 40-42 4Ref 4Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.Supports the specific first-cycle and cumulative live-birth rates by age (approximately 29.5% first-cycle and 65% cumulative by cycle six overall, versus about 12% and 31.5% for ages 40-42), showing age and cycle number driving IVF outcomes.. Reading about the number of ivf cycles and where diminishing returns after multiple IVF cycles typically set in fills out this picture far more directly than any single AMH result could. Age, not a hormone level drawn at one point in time, is what these large datasets show driving the curve.

Where AMH Does Earn Its Keep: Planning, Not Prediction

AMH's most legitimate use is forward planning, especially around egg freezing. A systematic review of planned oocyte cryopreservation found markedly higher cumulative live-birth rates when eggs were frozen at a younger age and when more mature eggs were banked per cycle — a relationship built on the number of eggs actually retrieved, which AMH helps anticipate before treatment starts 5Ref 5Hirsch A, et al. (2024).Planned oocyte cryopreservation: a systematic review and meta-regression analysis.Supports that cumulative live-birth rates after planned egg freezing are markedly higher when eggs are frozen younger and when more mature oocytes are banked — the practical planning use of an AMH-informed oocyte count, distinct from a live-birth guarantee..

Banking enough eggs, not hitting a specific AMH threshold, is the number worth tracking. For women expected to yield relatively few eggs per retrieval, this is also where a clinician might raise mini-ivf and natural-cycle IVF as a lower-medication alternative worth weighing against a standard stimulation protocol.

This is also the honest limit of what AMH offers: it helps set expectations for how many eggs a cycle might produce, and by extension how many cycles it might take to bank enough for a reasonable shot, before treatment starts. It says much less about what happens after retrieval — fertilization, embryo development, and implantation are governed by factors AMH doesn't touch.

AMH Isn't the Only Test That Gets Oversold

AMH is not unique in being marketed ahead of what the evidence shows. Preimplantation genetic testing for aneuploidy has followed a similar pattern: a large multicenter randomized trial of good-prognosis patients found that adding this embryo test did not improve the ongoing-pregnancy rate compared with standard morphology-based embryo selection 6Ref 6Munné S, et al. (STAR Study Group) (2019).Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial.Supports the analogous case of PGT-A: a multicenter RCT in good-prognosis patients found no improvement in ongoing-pregnancy rate versus standard morphology-based selection, illustrating that a test can measure something real while still being oversold relative to the evidence..

The pattern in both cases is the same: a test that measures something real gets marketed as though it measures something it was never shown to measure. Reading a result correctly means asking what a study actually tested it against, not what a brochure implies — for AMH, that means asking whether a claim is about egg count or about a live birth, since only one of those is what the number was ever built to forecast.